Mironid

Estuary Biotherapeutics

This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Sidera

This company develops small molecule medicines for patients with metabolic, inflammatory and kidney diseases using human genetic research findings.

Nionyx Bio

The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Mighty Therapeutics

This company develops mitochondrial-targeted therapies for patients with rare genetic conditions like Barth syndrome and common age-related diseases.

ENYO Pharma

This digital health company develops small molecule therapeutics to treat patients with chronic kidney diseases and rare conditions like Alport syndrome.

Minoryx Therapeutic

This biotech company develops therapies for orphan central nervous system diseases, such as X-linked adrenoleukodystrophy, for patients with high unmet medical needs.